New data for Alzheimer’s drugs raise hopes, and questions, about bigger benefits over timenews2025-07-30T15:16:22+00:00July 30th, 2025|Endpoints News|
Cardiff’s targeted therapy shows early promise in KRAS-mutated colorectal cancersnews2025-07-30T13:13:58+00:00July 30th, 2025|Endpoints News|
GSK reaffirms goal of bringing Blenrep to US, reports fail with TIM-3 inhibitornews2025-07-30T11:35:50+00:00July 30th, 2025|Endpoints News|
Exelixis axes late-stage plans for TKI drug in head and neck cancer as Q2 earnings disappointnews2025-07-29T12:28:27+00:00July 29th, 2025|Endpoints News|
AstraZeneca reports revenue growth, pipeline tweaks as it ponders price cuts, direct-to-patient salesnews2025-07-29T11:07:58+00:00July 29th, 2025|Endpoints News|
Pharmaceutical tariffs included in new US-EU trade deal, White House saysnews2025-07-28T17:20:55+00:00July 28th, 2025|Endpoints News|
Roche doubles down on its Alzheimer’s ambitions as next-gen amyloid-lowering drug excites scientistsnews2025-07-28T15:18:41+00:00July 28th, 2025|Endpoints News|
Recognify’s schizophrenia drug fails mid-stage test, backer atai’s stock dipsnews2025-07-28T11:08:08+00:00July 28th, 2025|Endpoints News|
Celcuity posts Phase 3 win in breast cancer, setting up challenge to Novartis and Rochenews2025-07-28T10:00:40+00:00July 28th, 2025|Endpoints News|
Memo Therapeutics plots Phase 3 trial for kidney infection drug despite mid-stage study missnews2025-07-25T05:00:13+00:00July 25th, 2025|Endpoints News|
